ENTRY       D00535                      Drug
NAME        Vigabatrin (JAN/USP/INN);
            Sabril (TN)
PRODUCT     SABRIL (Lundbeck Pharmaceuticals LLC)
            SABRIL (Lundbeck Pharmaceuticals LLC)
  GENERIC   VIGABATRIN (Actavis Pharma)
            VIGABATRIN (Actavis Pharma)
            VIGABATRIN (Amneal Pharmaceuticals NY LLC)
            VIGABATRIN (Amneal Pharmaceuticals NY LLC)
            VIGABATRIN (Amneal Pharmaceuticals NY LLC)
            VIGABATRIN (Ascend Laboratories)
            VIGABATRIN (Aurobindo Pharma Limited)
            VIGABATRIN (Aurobindo Pharma Limited)
            VIGABATRIN (Biocon Pharma)
            VIGABATRIN (Cadila Healthcare Limited)
            VIGABATRIN (Cipla USA)
            VIGABATRIN (Dr. Reddy's Laboratories Inc.,)
            VIGABATRIN (Dr. Reddy's Laboratories Inc.,)
            VIGABATRIN (Edenbridge Pharmaceuticals LLC.)
            VIGABATRIN (Hikma Pharmaceuticals USA)
            VIGABATRIN (Novadoz Pharmaceuticals LLC)
            VIGABATRIN (Par Pharmaceutical)
            VIGABATRIN (Zydus Pharmaceuticals (USA))
            VIGABATRIN FOR ORAL SOLUTION (Camber Pharmaceuticals)
            VIGABATRIN FOR ORAL SOLUTION USP, 500 MG (Hikma Pharmaceuticals USA)
            VIGADRONE (Upsher-Smith Laboratories)
            VIGADRONE (Upsher-Smith Laboratories)
FORMULA     C6H11NO2
EXACT_MASS  129.079
MOL_WEIGHT  129.157
CLASS       Neuropsychiatric agent
             DG03199  Antiepileptic agent
              DG02037  GABA mimetic antiepileptic
REMARK      Same as: C07500
            Therapeutic category: 1139
            ATC code: N03AG04
            Product: D00535<JP/US>
EFFICACY    Anticonvulsant, Antiepileptic
  DISEASE   Infantile spasms [DS:H01460]
COMMENT     Fatty acid derivative
TARGET      ABAT [HSA:18] [KO:K13524]
  PATHWAY   hsa04727(18)  GABAergic synapse
INTERACTION  
STR_MAP     map07033  Anticonvulsants
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N03 ANTIEPILEPTICS
               N03A ANTIEPILEPTICS
                N03AG Fatty acid derivatives
                 N03AG04 Vigabatrin
                  D00535  Vigabatrin (JAN/USP/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Anticonvulsants
              Gamma-aminobutyric Acid (GABA) Augmenting Agents
               GABA Agents, Other
                Vigabatrin
                 D00535  Vigabatrin (JAN/USP/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               113  Antiepileptics
                1139  Others
                 D00535  Vigabatrin (JAN/USP/INN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               DG02037  GABA mimetic antiepileptic
                D00535  Vigabatrin
            Drug classes [BR:br08332]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               D00535  Vigabatrin
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Transferases (EC2)
               Aminotransferase
                ABAT
                 D00535  Vigabatrin (JAN/USP/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D00535
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D00535
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D00535
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D00535
DBLINKS     CAS: 60643-86-9
            PubChem: 7847601
            ChEBI: 63638
            LigandBox: D00535
            NIKKAJI: J82.341D
ATOM        9
            1   C1c C    17.4113  -16.5555
            2   C1b C    18.6260  -15.8548
            3   N1a N    16.1967  -15.8607
            4   C2b C    17.4172  -17.9570
            5   C1b C    19.8406  -16.5438
            6   C6a C    21.0553  -15.8490
            7   O6a O    22.2641  -16.5381
            8   O6a O    21.0494  -14.4416
            9   C2a C    16.2033  -18.6648
BOND        8
            1     1   2 1
            2     1   3 1
            3     1   4 1
            4     2   5 1
            5     5   6 1
            6     6   7 1
            7     6   8 2
            8     4   9 2
///
